CureVac
CureVac was a clinical-stage biopharmaceutical company specializing in mRNA-based therapeutics, vaccines, and cancer immunotherapies. It has been acquired by BioNTech.
Classification
Profile
Funding
Funding details not yet available.
Fundraising & market
To transform people's lives using proprietary mRNA technology to develop effective vaccines and treatments for infectious diseases, cancer, and rare diseases.
B2B/B2G: Healthcare systems, pharmaceutical partners, and government health agencies worldwide.
Up-front licensing fees & equity stakes - e.g., €400 M upfront from GSK for COVID-19/flu programs · Milestone payments - tied to IND, Phase II/III completions, regulatory approvals · Royalties on sales - percentage of commercial vaccine/therapy revenues (typical 5-15 %)
channel partners
BioNTech (acquirer), various pharmaceutical partners for development and distribution.
R&D, clinical trials, manufacturing, regulatory compliance
Proprietary mRNA technology platform, second-generation mRNA backbone, IP portfolio, scientific team.
R&D, clinical development, mRNA manufacturing, regulatory approval processes.
Strategic alliance management - dedicated partnership teams handling joint-development roadmaps, milestone tracking, and co-marketing plans · Scientific collaboration platforms - shared data portals, joint publications, and co-ownership of IP to deepen trust with academia · Investor & stakeholder communication - quarterly earnings calls, transparen
Competes with other mRNA developers like BioNTech and Moderna. Differentiated by its specific mRNA backbone technology and proprietary platform, though it was ultimately acquired by BioNTech.
Need for rapid vaccine development against infectious diseases, lack of effective treatments for rare diseases and cancer, and need for scalable mRNA manufacturing.
- The financial figures (cash runway, partnership values) are taken from the 2025 investor handout and the company’s restructuring announcement, both publicly filed with the German Federal Gazette【1†https://dcfmodeling.com/products/cvac-business-model-canvas】.
- Patent count and R&D spend are corroborated by the 2024 annual report and third‑party market‑analysis sites (e.g., PatSnap)【5†https://synapse.patsnap.com/article/what-are-the-primary-areas-of-focus-for-curevac】.
No investors recorded yet.